Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma

Weiling He1,2†, Di Xu3†, Zhuo Wang1†, Hui Wu2, Xianhong Xiang4†, Bing Tang2, Wenting Jiang1, Yongmei Cui1, Han Wang1, Neng Jiang1, Yu Sun1, Yangshan Chen1, Shuhua Li1, Minzhi Hou5, Yang Zhang6, Liantang Wang1 and Zun-fu Ke1*

Abstract

Background: Circulating tumor cells (CTC) shows great prospect to realize precision medicine in cancer patients.

Methods: We developed the NanoVelcro Chip integrating three functional mechanisms. NanoVelcro CTC capture efficiency was tested in stage III or IV lung adenocarcinoma. Further, ALK-rearrangement status was examined through fluorescent in situ hybridization in CTCs enriched by NanoVelcro.

Results: NanoVelcro system showed higher CTC-capture efficiency than CellSearch in stage III or IV lung adenocarcinoma. CTC counts obtained by both methods were positively correlated (r = 0.45, p < 0.05). Further, Correlation between CTC counts and pTNM stage determined by NanoVelcro was more significant than that determined by Cell-Search (p < 0.001 VS p = 0.029). All ALK-positive patients had 3 or more ALK-rearranged CTC per ml of blood. Less than 3 ALK-rearranged CTC was detected in ALK-negative patients. NanoVelcro can detect the ALK–rearranged status with consistent sensitivity and specificity compared to biopsy test. Furthermore, the ALK-rearranged CTC ratio correlated to the pTNM stage in ALK-positive patients. Following up showed that CTCs counting by NanoVelcro was more stable and reliable in evaluating the efficacy of Clozotinib both in the short and long run compared with CellSearch. Changing of NanoVlecro CTC counts could accurately reflect disease progression.

Conclusion: NanoVelcro provides a sensitive method for CTC counts and characterization in advanced NSCLC. ALK-rearrangement can be detected in CTCs collected from advanced NSCLC patients by NanoVelcro, facilitating diagnostic test and prognosis analysis, most importantly offering one noninvasive method for real-time monitoring of treatment reaction.

Keywords: Nanomaterials, Microfluidics, Circulating tumor cell, Lung cancer, Diagnostics
Background

Circulating tumor cells (CTC) are cancer cells that exist in the circulation system of patients with solid cancers, after detaching from primary tumor lesions. It is said that CTC holds great promise in tailoring treatment decision for cancer patients [1]. CellSearch system as the most classic CTC enrichment system based on detection of tumor cells that express epithelial cell adhesion molecule (EpCAM), was effective to predict prognosis of many cancers, especially breast and lung cancers [1–3]. Furthermore, it is the only method approved by the US Food and Drug Administration (FDA) for the enumeration of CTC in certain advanced cancers. Detection of 5 CTCs per 7.5 ml or higher can predict prognosis regardless of disease histology and molecular subtype, type of treatment, or whether the patient had recurrent or de-novo metastatic disease [4].

Over the past years, a diverse suite of techniques including biophysical (e.g., density gradient centrifugation devices, size-based filtration systems, cell dielectric properties-based isolation assays, microfluidics-based technologies, etc.) and biochemical (e.g., capture-agent-labeled immunomagnetic beads, CTCs-chip and nanoparticle enrichment devices, etc.) methodology-based enrichment assays by their different properties had been demonstrated [5, 6]. One such most widely-used CTC assay CellSearch mentioned above is based on the technique of capture-agent-coated magnetic beads. More recently, nanostructured cell-affinity substrate coated with cancer-cell capture agents (e.g., epithelial cell adhesion molecule antibody, anti-EpCAM) has also been applied to enrich and immobilize CTCs, exhibiting improved cell-capture efficiency [7–13]. However, the overall enrichment efficacy is still discontented by use of these techniques.

Previously, we pioneered a NanoVelcro Chip owning anti-EpCAM [14, 15] coated 3D-nanostructured substrate [16], showed enhanced CTCs enrichment efficacy compared to CellSearch [17] in prostate cancer. Our NanoVelcro Chip integrates three functional features: (1) anti-EpCAM coating for capturing EpCAM-positive cells through immunological reaction, (2) a silicon nanopillar (SiNP) substrate with special microstructured surfaces, which exhibits improved cell-capture efficiency owing to enhanced local topographic interactions [18] between the SiNP substrates and nanoscale cellular surface components [17], (3) an overlaid polydimethylsiloxane (PDMS) chip with a serpentine chaotic mixing channel [8, 19–21] forming special microfluidic that increased cell-substrate contact frequency. Despite the enhanced CTCs capture ability, the controlled study did not perform in lung cancer and the subsequent CTC cellular characterization (e.g., driver oncogene mutation status) consistency which is of great clinical significance for therapy guidance between the two methods weren’t further analyzed in this study.

As the most common sensitive gene mutations for lung cancer, a fusion gene between the anaplastic lymphoma kinase (ALK) gene and echinoderm microtubule associated protein-like 4 (EML4) was identified in 3% to 7% of unselected NSCLC patients [22], and further proved to be a potent oncogenic driver [23, 24]. Crizotinib as an ALK inhibitor [9, 24], was approved by the FDA for treating advanced ALK-positive NSCLC patients [10] and showed good therapeutic effect. Recently, the Vysis ALK Break-Apart FISH Probe Kit (Abbott Molecular, Inc.) was approved to detect ALK rearrangement status on small biopsies or fine-needle aspirated tissue. Considering the biopsy risk, medical cost and patient acceptance, it is difficult to repeatedly obtain tumor specimens, which are imperative in determining the therapeutic effect, exploring predictive biomarkers and choosing alternative treatment timely. In patients with advanced NSCLC, tumor specimen is more difficult to obtain because surgery is rarely a component of treatment [11] in advanced lung cancer patients. Thus, developing a noninvasive and effective assessment platform, that could predict whether patients can benefit from primary treatment and diagnosis if an ALK-rearrangement presents identifying NSCLC patients benefiting from Crizotinib treatment, is imperative and invaluable.

Based on the predicament faced above, our present study was to determine if NanoVelcro platform could capture CTC from the advanced NSCLC patient blood with improved efficiency compared to CellSearch system by utilizing similar enrichment technique. Moreover, the second endpoint of our study was to determine whether an ALK-rearrangement could be detected in CTCs enriched by NanoVelcro assay from ALK-positive advanced NSCLC patients, facilitating treatment strategy design and prognosis monitoring.

Materials and methods

Patients

This study was approved by the institutional ethics committee of the First Affiliated Hospital of Sun Yat-sen University, China (A-084). Totally forty-one lung cancer patients were enrolled in our study in which twenty-one patients with positive ALK-rearranged status in tumor tissues were set as observation group and twenty patients with negative ALK-rearranged status were set as control, and consistent consent to publish from all the participants had obtained. All the forty-one patients were with stage III or IV lung adenocarcinoma. Peripheral blood samples were collected from all the patients before initiating standard treatment. In the follow up study, samples
were collected from one patient undergoing Crizotinib treatment for 8 months. All blood samples (1 ml per person) were collected into EDTA-containing vacutainer tubes (BD bioscience) and then proceed to further procedures (Fig. 1).

**NanoVelcro chip fabrication**

NanoVelcro CTC chip is composed of three parts: (1) a serpentine chaotic mixer chip made of polydimethylsiloxane (PDMS), (2) a patterned silicon nanowire (SiNW) substrate with high-affinity anti-EpCAM coating, and (3) a home-machined holder set to sandwich a well-aligned PDMS mixer chip with the SiNW substrate (Fig. 2). The PDMS mixer chips were fabricated using a standard soft-lithography method. Consistent channel structure and PDMS thickness were achieved using this method. The fabrication method for the SiNW substrate was reported earlier [7, 17]. After DI water rinsing and nitrogen blow-dry, the substrate was ready for subsequent streptavidin coating. Streptavidin coating was also conducted following a previously established protocol.

Prior to each test, the PDMS chaotic mixer chip and streptavidin-coated substrate were sandwiched together using a home-machined holder set consisting of (1) one stainless steel bottom plate, (2) one poly methyl methacrylate (PMMA) clapboard, (3) one stainless steel top frame, and (iv) a screw at each corner (Fig. 1a). Finally, the top frame was anchored to the PMMA clapboard and bottom plate by screws to form a constant pressure seal to prevent leakage. The anti-EpCAM solution was then loaded into the channel by a syringe pump (KDS 200, KD scientific) for conjugation. Before sample injection, the channel required multiple PBS 1× washings to remove free anti-EpCAM. This may dramatically shorten the time spent on whole chip scanning while reducing total reagent consumption for each test.

**FISH assay on tumor tissue**

The dual-color FISH assay using the Vysis LSI ALK Break Apart Rearrangement Probe Kit (Abbott Molecular) is completed following procedure instruction. The Vysis ALK Break Apart FISH Probe Kit consists of two probes...
adjacent to the 3′ (red) and 5′ (green) ends of ALK. In cells with a native ALK status, the overlapping of probes results in a fused (3′ 5′, yellow) signal. The two characteristic ALK-rearrangement split patterns are the split of the 3′ (red) and 5′ (green) probes (a distance of more than two signal diameters was considered a split) or an isolated single or amplified 3′ (red) signal. Signals were enumerated in at least 100 tumor nuclei, and FISH-positive cases were defined as those with more than 15% split or isolated signals [11, 25].

**CTC enrichment by CellSearch and NanoVelcro**

CTC enrichment by NanoVelcro was performed on 1.0 ml of blood similar to previous report [7, 17]. CTC were enumerated by using CellSearch (Veridex) from 7.5 ml of blood as previously described [11, 25]. In order to visualize captured cells on SiNW substrate, additional steps of immunocytochemistry were employed by loading the microchannel with 100 μl of fluorophore-labeled antibody [anti-TTF-1 (Thyroid transcription factor 1), anti-CEA (carcinoembryonic antigen), anti-CK-7 (cytokeratin-7) and p63 (Dako, Glostrup, Denmark)] solution (20 μl/1 ml initial concentration) for overnight incubation at 4 °C after the step of cell permeabilization. After image acquisition, CTCs were identified by combination of a series of criteria: positive staining of anti-cytokeratin (PE) and DAPI; negative staining of anti-CD45 (FITC); and characteristic phenotypes and morphology of cancer cells. The cells with phenotypes of positive anti-CD45 (FITC) and DAPI, but negative anti-cytokeratin (PE) were excluded as lymphocytes. Experimental approaches used to characterize CTC collecting from NanoVelcro are detailed in Additional file 1.

**FISH assay of NanoVelcro enriched CTC**

Each step of the FISH method was optimized for highest cell recovery. Hybridization was performed by using the Vysis LSI Dual Color ALK Break Apart Rearrangement Probe Kit [Abbott Molecular, (37 °C, pepsin (Sigma, USA) at 10% in an HCL 0.01 N)]. The ALK status was validated blindly by an experienced cytogenetician. FISH signals were analysed either manually using an epi-fluorescence microscope (Nikon), or an automated
**Results**

**NanoVelcro with higher efficiency than CellSearch**

NanoVelcro can capture typical CTC in blood of advanced NSCLC patients, characterized as CD45-negative and CK-positive (Fig. 3a). In accordance with previously report [17], CTC counts were higher by NanoVelcro than CellSearch (178.17±81.45 vs. 37.95±19.54 per 7.5 ml, p < 0.05) (Fig. 3b). More importantly, CTC counts obtained with both methods were moderately correlated (r = 0.45, p < 0.05) (Fig. 3c).

CTC were detected in all advanced NSCLC ALK-positive and ALK-negative patients using NanoVelcro, meanwhile in 19 of 21 (90.49%) advanced NSCLC ALK-positive patients and 18 of 20 (90%) negative patients by CellSearch (Tables 1, 2). Mean values of 35.67±18.02 and 167.50±80.33 CTC per 7.5 ml were detected by CellSearch and NanoVelcro in ALK-positive patients, respectively (Table 1). Meanwhile, they detected 40.35±21.22 and 189.38±82.37 CTCs per 7.5 ml in ALK-negative patients respectively (Table 2). Further analysis showed that Correlation between CTC counts and pTNM stage determined by NanoVelcro was more significant than that determined by CellSearch (p<0.001 vs p=0.029, Fig. 3d).

**Detecting ALK-rearrangement in CTC captured by NanoVelcro**

All patients were determined by an ALK-rearrangement FISH Probe Kit in biopsies of primary tumors or metastases. ALK-positive patients were defined as those with more than 15% split or isolated signals (Fig. 4). Twenty-one patients presented ALK-positive status with the percentage of ALK-rearranged cells ranging from 19 to 96% (Table 1). All 21 ALK-positive patients were examined with a negative FISH result (Table 2).

By NanoVelcro, CTC harboring an ALK-rearrangement were detected in all ALK-positive patients with a mean value of 15.71±10.33 CTC per ml (Table 1). All ALK-positive patients had 3 or more ALK-rearranged CTCs per ml of blood (Fig. 5a). No or only 2 ALK-rearranged CTC was detected in blood of the 20 patients with ALK-negative NSCLC (mean, 0.45 CTC per ml; Table 2). Receiver operating characteristic curve analysis indicated that a cutoff value of 3 ALK-rearranged CTC per ml blood had a sensitivity of 100% and a specificity of 100% (Fig. 5a). The concordance between FISH based on NanoVelcro captured-CTC and tumor specimen quantified by the κ coefficient was 99.99% (Fig. 5b), area under ROC curve was approximately 0.989 (Fig. 6). Mean percentages of ALK-rearranged CTC were 64.76±24.03% in ALK-positive patients and were 1.6% in ALK-negative patients (Tables 1, 2).

In order to differentiate ALK-positive and ALK-negative patients, the optimal cutoff of ALK-rearranged CTC counts was evaluated using receiver operating characteristic (ROC) curve to maximize the sum of sensitivity plus specificity in terms of ALK status prediction.

**ALK-rearranged status of CTC aid treatment strategy decision**

Detection and genomic analysis of CTC is anticipated to facilitate precision medicine as a potential real-time and noninvasive method in replace of invasive biopsy. Traditionally, the ALK mutation can only be tested in the tumor biopsy, which is very difficult to obtain under certain circumstance. This study offered one alternative method to identify ALK mutations from CTC isolated by NanoVelcro. Current strategies for isolating CTC are limited to complex analytic approaches that generate low yield and purity. In this study, ALK-rearrangement CTC was consistently detected in all patients harboring this
mutation confirmed by the tumor specimen. In 21 ALK-positive patients, the ratio of ALK-rearrangement CTC positively correlated to the ratio of ALK positive cells in tumor tissue (Fig. 7a). This assay for detecting ALK mutations in advanced NSCLC patients through CTC captured by NanoVelcroC may be applied to screen ALK positive patient eligible for ALK-targeted treatment.

**Dynamically monitoring NSCLC progression through counting CTC during Crizotinib Treatment**

Under selective pressure of therapy intervention, resistance is inevitable in anti-tumor strategy. Even patients treated with molecular targeted drugs will acquire resistance, commonly as a result of a secondary mutation. Thus, developing an effective method to monitor the treatment reaction and unveil the underlying resistance mechanism is invaluable. We demonstrated that CTC characterization owns prognostic value as well as the CTC counts. In ALK-positive patient, the ALK-rearrangement CTC ratio correlated to the pTNM stage (Fig. 7b), indicating that increased ALK-rearrangement CTC may predict advanced disease progression.

Blood samples were collected from one patient for CTC enumeration by both methods during Crizotinib treatment for 8 months, meanwhile several times of radiological examination (CT scan) were performed according to the requirement of disease evaluation. Both NanoVelcro and CellSearch CTC counts initially
| Patient | Sex | Age (y/o) | Smoking status (y/o) | Adenocarcinoma subtype | Clinical stage | Tumor Biopsy origin | % of rearranged cells | CTCs by NanoVelcro Rearranged CTCs (per ml) | % of rearranged CTCs | Total CTCs (per ml) | CTC number by CellSearch (7.5 ml) |
|---------|-----|----------|---------------------|-----------------------|----------------|---------------------|----------------------|---------------------------------|-------------------|-----------------|-------------------------|
| P1      | F   | 51       | 2                   | Papillary             | II             | Pleura (MS)         | 43                   | 6                               | 35                | 17              | 46                       |
| P2      | F   | 47       | 0                   | Mucinous              | IV             | Lung (PT)           | 38                   | 5                               | 39                | 13              | 23                       |
| P3      | M   | 43       | 0                   | Papillary             | II             | Node (MS)           | 27                   | 3                               | 22                | 9               | 0                        |
| P4      | M   | 68       | 15                  | Mucinous              | IV             | Pleura (MS)         | 57                   | 27                              | 87                | 31              | 71                       |
| P5      | M   | 54       | 21                  | Papillary             | IV             | Bone (MS)           | 96                   | 32                              | 87                | 37              | 29                       |
| P6      | M   | 69       | 41                  | Solid                 | IV             | Node (MS)           | 86                   | 21                              | 70                | 30              | 41                       |
| P7      | F   | 37       | 0                   | Mucinous              | III            | Node (MS)           | 41                   | 7                               | 47                | 15              | 51                       |
| P8      | F   | 58       | 0                   | Solid                 | IV             | Lung (PT)           | 47                   | 17                              | 90                | 19              | 19                       |
| P9      | F   | 57       | 0                   | Solid                 | IV             | Lung (PT)           | 37                   | 21                              | 75                | 28              | 51                       |
| P10     | F   | 63       | 0                   | Mucinous              | IV             | Lung (PT)           | 82                   | 36                              | 84                | 43              | 27                       |
| P11     | M   | 71       | 10                  | Mucinous              | III            | Pleura (MS)         | 31                   | 9                               | 43                | 21              | 33                       |
| P12     | M   | 41       | 0                   | Mucinous              | IV             | Node (MS)           | 71                   | 25                              | 86                | 29              | 34                       |
| P13     | F   | 82       | 0                   | Mucinous              | IV             | Brain (MS)          | 51                   | 17                              | 100               | 17              | 19                       |
| P14     | F   | 35       | 0                   | Solid                 | III            | Lung (PT)           | 19                   | 3                               | 33                | 8               | 0                        |
| P15     | F   | 47       | 0                   | Solid                 | III            | Lung (PT)           | 47                   | 9                               | 100               | 9               | 37                       |
| P16     | M   | 49       | 0                   | Papillary             | III            | Node (MS)           | 49                   | 3                               | 50                | 6               | 48                       |
| P17     | F   | 53       | 12                  | Mucinous              | IV             | Node (MS)           | 59                   | 24                              | 83                | 29              | 61                       |
| P18     | F   | 49       | 1                   | Solid                 | IV             | Lung (PT)           | 42                   | 19                              | 58                | 33              | 48                       |
| P19     | F   | 67       | 0                   | Mucinous              | III            | Lung (PT)           | 36                   | 8                               | 47                | 17              | 31                       |
| P20     | M   | 69       | 19                  | Solid                 | III            | Node (MS)           | 38                   | 10                              | 48                | 21              | 29                       |
| P21     | M   | 45       | 0                   | Solid                 | IV             | Lung (PT)           | 79                   | 28                              | 76                | 37              | 51                       |

**Table 1 Numbers and Percentages of ALK-Rearranged Cells in Tumors and in CTC of ALK-Positive Patients**

**Notes:** ALK anaplastic lymphoma kinase, CTC circulating tumor cell, F female, M male, MS metastatic site, PT primary tumor.
| Patient | Sex | Age (y/o) | Smoking status (y/o) | Adenocarcinoma subtype | Clinical stage | Tumor Biopsy origin | CTCs by NanoVelcro | CTC number by CellSearch (7.5 ml) |
|---------|-----|-----------|----------------------|------------------------|----------------|---------------------|-------------------|----------------------------------|
|         |     |           |                      |                        |                | Rearranged CTCs (per ml) | % of rearranged CTCs | Total CTCs (per ml) |                               |
| PN1     | M   | 39        | 10                   | Mucinous               | IV             | Bone (MS)           | 2                 | 7                  | 27                              | 23 |
| PN2     | F   | 47        | 0                    | Solid                  | III            | Lung (PT)           | 0                 | 0                  | 14                              | 36 |
| PN3     | F   | 71        | 0                    | Papillary              | III            | Lung (PT)           | 0                 | 0                  | 7                               | 14 |
| PN4     | F   | 52        | 0                    | Solid                  | IV             | Pleura (MS)         | 0                 | 0                  | 28                              | 39 |
| PN5     | M   | 67        | 30                   | Papillary              | IV             | Node (MS)           | 0                 | 1                  | 21                              | 71 |
| PN6     | F   | 54        | 4                    | Solid                  | III            | Node (MS)           | 0                 | 1                  | 16                              | 49 |
| PN7     | M   | 45        | 0                    | Mucinous               | IV             | Brain (MS)          | 0                 | 0                  | 32                              | 53 |
| PN8     | M   | 37        | 0                    | Solid                  | IV             | Lung (PT)           | 0                 | 2                  | 36                              | 57 |
| PN9     | F   | 75        | 0                    | Solid                  | IV             | Pleura (MS) N/A     | 0                 | 0                  | 25                              | 43 |
| PN10    | F   | 58        | 0                    | Mucinous               | III            | Lung (PT)           | 0                 | 0                  | 21                              | 38 |
| PN11    | F   | 63        | 0                    | Solid                  | III            | Pleura (MS)         | 0                 | 0                  | 15                              | 57 |
| PN12    | M   | 54        | 27                   | Mucinous               | IV             | Node (MS)           | 0                 | 1                  | 35                              | 29 |
| PN13    | M   | 77        | 0                    | Solid                  | III            | Lung (PT)           | 0                 | 0                  | 19                              | 0  |
| PN14    | F   | 39        | 3                    | Solid                  | IV             | Node (MS)           | 0                 | 0                  | 42                              | 21 |
| PN15    | F   | 53        | 0                    | Solid                  | IV             | Bone (MS)           | 0                 | 2                  | 37                              | 69 |
| PN16    | F   | 61        | 0                    | Mucinous               | III            | Lung (PT)           | 0                 | 0                  | 6                               | 0  |
| PN17    | M   | 60        | 0                    | Papillary              | IV             | Node (MS)           | 0                 | 0                  | 38                              | 57 |
| PN18    | M   | 71        | 47                   | Solid                  | III            | Lung (PT)           | 0                 | 0                  | 23                              | 39 |
| PN19    | F   | 47        | 0                    | Mucinous               | III            | Lung (PT)           | 0                 | 0                  | 20                              | 41 |
| PN20    | F   | 63        | 0                    | Papillary              | IV             | Bone (MS)           | 0                 | 0                  | 43                              | 71 |

**ALK** anaplastic lymphoma kinase, **CTC** circulating tumor cell, **M** male, **MS** metastatic site, **N/A** not available, **PT** primary tumor
dropped after the start of Crizotinib, accompanied by imaging relieve. All these changes keep in accordance to the improvement of clinical symptoms, indicating Crizotinib treatment effect. After treatment for 6 months, obvious tumor shrinkage presented in CT scan, while CTC counts of both methods dropped to the same level. However, in next 2 month, CTC counts from CellSearch rebounded abnormally disaccording with the tumor disappearing on CT scan. Meanwhile,
NanoVlecro CTC counts presented further decrease, accurately reflecting disease progression (Fig. 8).

Discussion
Our present study showed great improvement in CTC-capture efficiency with NanoVelcro chip compared with CellSearch in stage III or IV lung adenocarcinoma, which is in accordance with our previous findings [17], however the results need to be further validated by enlarging the sample size. Furthermore, CTC counts of the two methods positively correlated. Correlation between CTC counts and pTNM stage determined by NanoVelcro was more significant than that determined by CellSearch. CTC characterization analysis demonstrated that CTCs captured by NanoVelcro well reflect the ALK mutation status in tumor tissue, the ratio of ALK-rearrangement in CTCs positively correlated to that in tumor tissue. Furthermore, ALK-rearrangement CTC ratio detected by NanoVelcro correlated to the pTNM stage indicating that increased ALK-rearrangement CTCs may represent advanced disease status. Interestingly, as for therapeutic effect monitoring, in the short term (within the first 6 months), the two methods showed good consistency in evaluating the treatment efficacy of Clozotinib, but in the long run (the 8th month), compared with CellSearch, CTC counting by NanoVelcro was more stable and reliable in evaluating the efficacy of Clozotinib. Whilst, decreasing of NanoVelcro CTC counts could accurately reflect disease remission evaluated by chest CT image.

The ability to identify, isolate, propagate and characterize CTC subpopulations with noninvasive CTC-capture platform could deepen the understanding of blood metastasis mechanism, facilitate accurate evaluation of disease progression, continuously monitor the CTC (e.g. number, molecular and genetic characters) change to guide therapy. Although CellSearch is the only cell-affinity assay approved by the FDA and CTC numeration based on this platform and was proved to be an accurate prognostic indicator [1–3], whereas, it is gradually being depreciated due to “important limitations” in selecting CTC based on EpCAM which could lead to comparatively limited number of captured CTCs of epithelial cell phenotype only. However, metastasis begin with the epithelial–mesenchymal transition (EMT), in which tumor cells lose many of their ‘epithelial’ characteristics and become more like mesenchymal cells with the
ability to spread and invade tissue [26]. Thus, this kind of cell capture technique is likely to miss the cells of mesenchymal cell phenotype which is EpCAM-negative. To increase capture efficiency of CTCs, we developed this NanoVelcro platform detect CTC based on the similar immunological mechanism of CellSearch, but combined with special microstructured surfaces to strengthen topographic interactions and microfluidics to facilitate contact frequency. Microfluidics design may increase the contact between CTC and EpCAM coated substrate and intensify the immunological recognition affinity, maximizing the capture potential which CellSearch can't accomplish. Expectedly, this platform identified more than several times of CTC than CellSearch in advanced NSCLC patient, showing improved capture efficiency. Additionally, since CellSearch may miss EpCAM-negative CTC, this drawback may be partially compensated by strengthened topographic interactions between CTC and NanoVelcro microstructured surfaces [27], this is also involved in our device by using special microstructured surfaces.

In our study, CTC characterization analysis demonstrated that ALK-rearrangement status in NanoVelcro captured CTCs showed reliable consistency with that in the tumor specimen, and ALK-rearrangement was consistently detected in CTC from lung cancer patients harboring this rearrangement. Traditionally, ALK mutation status can be only determined by tissue
biopsy, which is invasive, expensive and time consuming. We demonstrated NanoVelcro platform that can non-invasively and accurately determine ALK mutations status in advanced NSCLC patients. Thus, NanoVelcro may be a surrogate to screen ALK positive patients eligible for ALK-targeted treatment, and CTCs captured by such technique and further FISH may resolve the problem of monitoring the genomic profiling of tumor, which may predict the treatment efficacy of Crizotinib and is hard to be achieved by traditionally tumor biopsy analysis. Furthermore, ALK-rearrangement CTC ratio detected by NanoVelcro correlated to pTNM stage indicating that increased ALK-rearrangement CTCs may represent advanced disease status.

Then we further demonstrate the ability to identify CTC number changes by NanoVelcro in response to Crizotinib therapies in one metastatic NSCLC patients. The results showed that, compared with CellSearch, CTCs counting by NanoVelcro was more stable and reliable in evaluating the efficacy of Clozotinib both in the short and long run. Whilst, changing of NanoVelcro CTC counts could accurately reflect disease progression. This might be due to the fact that the NanoVelcro assay can more accurately reflect the true number of CTCs. Our results are simillar to those reported [28, 29]. As the NanoVelcro generally presented much higher capture efficiency compared to the CellSearch™ assay, CTC counts by the NanoVelcro yield a wider dynamic range and may be a better predictor of disease progression [7]. Whilst, decreasing of NanoVelcro CTC counts could accurately reflect disease remission evaluated by chest CT image. Thus, NanoVelcro can be used to dynamically monitor the tumor morphology changes through analyzing CTC avoiding traditional tumor biopsy.

Briefly, NanoVelcro platform showed improved CTC-capture efficiency than CellSearch system, and the ALK-rearrangement status of captured CTCs kept in accordance with results from tumor specimen. This platform is primarily demonstrated to be an accurate, non-invasive and real-time detection of ALK mutations in treatment-naive patients with stage III or IV lung adenocarcinoma, optimizing the selection of ALK-inhibitor eligible patients and the dynamic monitoring of therapy reaction. Promisingly, Since NanoVelcro captured CTC are alive, these cells could potentially be expanded ex vivo for further molecular interrogation. Our future efforts will be devoted to preserve patient-derived CTC lines to select potential therapies options for individual cancer patients. We will also attempt to utilize NanoVelcro to predict the treatment reaction based on real-time monitoring the CTC counts and characterization changes in larger clinical cohorts to further confirm our findings.

Conclusion
In this study, ALK-rearrangement can be detected in CTCs captured by Nano Velcro system, presenting high concordance with matched primary tumor tissues. Correlation between CTC counts and pTNM stage determined by NanoVelcro was more significant than that determined by CellSearch. Whilst, the therapeutic efficacy of Clozotinib can be reliably respond by NanoVelcro assay and the changing of NanoVelcro CTC counts could accurately reflect disease progression. With CTCs capture and their corresponding ALK detection, dynamic monitoring of treatment effect for lung cancer patients could be realized during the process of Crizotinib treatment.

Additional file

Additional file 1. Supplementary data.

Authors’ contributions
ZK conceived and designed the experiments. DX, ZW and XX performed the experiments. HW, BT, and HW analyzed the experiments data. YC carried out statistical analysis. WJ, NJ, YS, YC wrote the manuscript. SL and MH collected the blood and tissue samples. YZ and LW reviewed the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan Road II, Guangzhou 510080, Guangdong, People's Republic of China. 2 Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, People's Republic of China. 3 Department of Thoracic Surgery, The Central Hospital of Wuhan, No.26 Shenli Street, Jiang'nan District, Wuhan 430014, Hubei, China. 4 Department of Interventional Radiology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong, People's Republic of China. 5 Department of Gynecology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, Guangdong, People's Republic of China. 6 Biomedical Engineering, University of Texas at El Paso, 500 West University Avenue, El Paso, TX 79968, USA.

Acknowledgements

The datasets supporting the conclusions of this article are included within the article and the additional file.

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and the additional file.

Consent for publication

We have obtained consistent consent to publish from the participants.

Ethics approval and consent to participate

This study was approved by the institutional ethics committee of the First Affiliated Hospital of Sun Yat-sen University, China.

Funding

This work was supported by Grants from the National Natural Science Foundation of China (30900650, 81372501, 81572260, 81871994, 81701834 and 81773299), the Guangdong Natural Science Foundation (2011B031800025,
References

1. Beij N, Jager A, Sleijfer S. Circulating tumor cell enumeration by the Cell Search system: the clinician’s guide to breast cancer treatment? Cancer Treat Rev. 2015;41(2):144–50.
2. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406–14.
3. Wang J, Wang K, Xu J, Huang J, Zhang T. Prognostic significance of circulating tumor cells in non-small-cell lung cancer patients: a meta-analysis. PLoS ONE. 2013;8(11):e78070.
4. Zhang J, Wang HT, Li BG. Prognostic significance of circulating tumor cells in small-cell lung cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(19):8429–35.
5. Cristofanilli M. Circulating tumour cells: telling the truth about metastasis. Lancet Oncol. 2014;15(4):365–6.
6. Parkinson DR, Dracopoli N, Petty BG, et al. Considerations in the development of circulating tumour cell technology for clinical use. J Transl Med. 2012;10:138.
7. Stroock AD, Dertinger SK, Ajdari A, Mezic I, Stone HA, Whitesides GM. Chaotic mixer for microchannels. Science. 2002;295(5555):647–51.
8. Wang S, Wang H, Jiao J, et al. Three-dimensional nanostructured substrates toward efficient capture of circulating tumor cells. Angewandte Chemie. 2009;48(47):8970–7 (international ed. in English).
9. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res. 2009;69(14):5627–9.
10. Fischer KE, Alemann BJ, Tao SL, et al. Biomimetic nanowire coatings for next generation adhesive drug delivery systems. Nano Lett. 2009;9(2):716–20.
11. Wang S, Liu K, Liu J, et al. Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angewandte Chemie. 2011;50(13):3084–8 (international ed. in English).
12. Liu WF, Chen CS. Cellular and multicellular form and function. Adv Drug Deliv Rev. 2007;59(13):1319–28.
13. Riethdorf S, Fritsche H, Muller V, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the Cell Search system. Clin Cancer Res. 2007;13(3):920–8.
14. Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.
15. Talasz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA. 2009;106(10):3970–5.
16. Nagrath S, Sequist LV, Mahesanar S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.
17. Adams AA, Okagbare PI, Feng J, et al. Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. J Am Chem Soc. 2008;130(27):8633–41.
18. Zheng S, Lin H, Liu JQ, et al. Membrane microfilter device for selective capture, electrolysis and genomic analysis of human circulating tumor cells. J Chromatogr A. 2007;1162(2):154–61.
19. Pailier E, Adam J, Barthelemy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013;31(18):2273–81.
20. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer. 2011;17(7):827–35.
21. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer undergoing epithelial marker-dependent and -independent approaches. J Thorac Oncol. 2012;7(2):306–15.
22. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the Cell Search Assay and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129(7):1651–60.
23. Farace F, Massard C, Vrindon N, et al. A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105(6):847–53.
24. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35(1):122–8.
25. Liu J, Williams BA, Gwirtz RM, Wold BJ, Quake S. Enhanced signals and fast nucleic acid hybridization by microfluidic chaotic mixing. Angewandte Chemie. 2006;45(22):3618–23 (international ed. in English).
26. Foley JQ, Mashadi‑Hossein A, Fu E, Finlayson BA, Yager P. Experimental and model investigation of the time‑dependent 2‑dimensional distribution of binding in a herringbone microchannel. Lab Chip. 2008;8(4):557–64.
27. Mitchell MJ, Castellanos CA, King MR. Surfactant functionalization induces robust, differential adhesion of tumor cells and blood cells to charged nanotube‑coated biomaterials under flow. Biomaterials. 2015;56:179–86.
28. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, Greystoke A, Ward TH, Fennalschi J, Hughes A, Clack G, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol. 2011;29:1556–63.
29. Lu YT, Zhao J, Shen Q, Garcia MA, Wu D, Hou S, Song M, Xu X, Ouyang WH, Ouyang WW, et al. NanoVelcro Chip for CTC enumeration in prostate cancer patients. Methods. 2013;64:144–52.